Mechanisms of Cholestatic Injury and Emerging Therapeutic Strategies
Nov
2026
Description
This session explores the cellular and molecular drivers of cholestatic liver disease and emerging therapeutic strategies utilizing biliary gene therapy. Presentations examine the impact of impairments in biliary transport and signaling in promoting cholestatic injury, inflammation, and fibrosis.
Presentations
11:00 AM
- 11:15 AM
Convention Center - Bluebird Ballroom 3DEF
Liver-Specific Tjp2 Deficiency in a Humanized Bile Acid Mouse Model Drives Cholestatic Injury via Immune Activation and Metabolic Suppression
Thi Hao Vu, PhD | Abstract Presenter
11:15 AM
- 11:30 AM
Convention Center - Bluebird Ballroom 3DEF
Loss of biliary adherens junctions results in primary sclerosing cholangitis-like cholestatic injury
Vik Meadows, PhD | Abstract Presenter
11:30 AM
- 11:45 AM
Convention Center - Bluebird Ballroom 3DEF
Biliary gene therapy
Pervin K Choksi, Bachelors | Abstract Presenter
11:45 AM
- 12:00 PM
Convention Center - Bluebird Ballroom 3DEF
Engineering Injury-Resistant Functional Biliary Trees with Enhanced Drug Efflux Capacity
Shiwen Ma | Abstract Presenter
12:00 PM
- 12:15 PM
Convention Center - Bluebird Ballroom 3DEF
Biliary cGAS-STING signaling mediates neutrophilic inflammation and fibrosis in cholestatic liver disease
Mobin Ibne Mokbul, MD | Abstract Presenter
12:15 PM
- 12:30 PM
Convention Center - Bluebird Ballroom 3DEF
Beyond Gilbert Syndrome: heterozygous UGT1A1 c.41_40dup defines a distinct cholangiopathic phenotype in young adults with Unexplained Chronic Cholestasis
Mario Romeo, MD | Abstract Presenter
